How much funding has Immunovant raised?

Immunovant has raised $585.0M in total funding, most recently a Growth Equity round.

When was Immunovant founded?

Immunovant was founded in 2018.

Where is Immunovant headquartered?

Immunovant is headquartered in New York, New York, United States.

What industry is Immunovant in?

Immunovant operates in Biotech, Healthcare.

How many employees does Immunovant have?

Immunovant has 51-200 employees.

Immunovant

IPO

Enabling normal lives with autoimmune disease

Public · New York, United States · Founded 2018 · $585.0M raised

Biotech

Healthcare

Headquarters: New York, New York
Employees: 51–200
Founded: 2018
Business Model: B2B
Website: immunovant.com

Total Funding: $585.0M
Last Round: $550.0M Growth EquityOct 2019
Rounds: 2
Type: Public

About

Immunovant is a clinical-stage immunology company developing FcRn inhibitor therapies to reduce harmful IgG autoantibodies in autoimmune disease. Its two investigational antibodies, IMVT-1402 and batoclimab, target FcRn as subcutaneous injections with tailored dosing across indications including Graves' disease, myasthenia gravis, and other IgG-mediated conditions.

Summary

Immunovant is a Biotech company based in New York, United States, founded in 2018. It has raised $585.0M in total across 2 rounds, most recently a $550.0M Growth Equity round in Oct 2019.

LinkedIn X (Twitter)